Happy to share our work: Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma JAMA Oncology. See our tweetorial and the terrific editorial by Georges Gebrael Gliceida Galarza, MD Neeraj Agarwal, MD, FASCO UroToday.com 1/7

Longitudinal CRP kinetics predicts immunotherapy response in NSCLC! First validation of CRP kinetics in Phase III clinical trial. Great cost-efficient and easy-to-implement tool for therapy monitoring Niklas Klümper Jonas Saal IEO_Bonn Rheinische Friedrich-Wilhelms-Universität Bonn Read: bit.ly/3WgZgs3